Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7) 7
index medicus (7) 7
male (7) 7
cardiovascular diseases (6) 6
female (6) 6
middle aged (6) 6
aged (5) 5
cardiovascular disease (5) 5
medicine, general & internal (5) 5
abridged index medicus (4) 4
adult (4) 4
cardiac & cardiovascular systems (4) 4
cerebral infarction (4) 4
double-blind method (4) 4
follow-up studies (4) 4
heart attacks (4) 4
myocardial infarction (4) 4
stroke (4) 4
drug dosages (3) 3
glucagon (3) 3
health risk assessment (3) 3
motivation (3) 3
prevention (3) 3
research (3) 3
risk factors (3) 3
safety (3) 3
acute coronary syndrome - drug therapy (2) 2
acute coronary syndromes (2) 2
agonists (2) 2
analysis (2) 2
angina (2) 2
angina pectoris (2) 2
association (2) 2
base-line (2) 2
blood pressure (2) 2
cardiovascular diseases - prevention & control (2) 2
cholesterol (2) 2
clinical trials (2) 2
coronary artery disease (2) 2
coronary heart disease (2) 2
death (2) 2
diabetes (2) 2
diabetes mellitus (2) 2
diagnosis (2) 2
disease control (2) 2
drug therapy (2) 2
efficacy (2) 2
fees & charges (2) 2
glucagon-like peptide 1 (2) 2
health risks (2) 2
heart diseases (2) 2
hemoglobin (2) 2
incidence (2) 2
ischemia (2) 2
kaplan-meier estimate (2) 2
life sciences (2) 2
liraglutide (2) 2
mortality (2) 2
myocardial-infarction (2) 2
patients (2) 2
pcsk9 (2) 2
peptides (2) 2
pharmaceuticals (2) 2
randomization (2) 2
risk (2) 2
risk analysis (2) 2
stroke - prevention & control (2) 2
therapy (2) 2
treatment outcome (2) 2
acceleration (1) 1
activating-factor acetylhydrolase (1) 1
acute coronary syndrome (1) 1
acute coronary syndrome - blood (1) 1
acute coronary syndrome - complications (1) 1
adolescent (1) 1
airway management (1) 1
angiosarcoma (1) 1
angiotensin-converting enzyme inhibitors (1) 1
antianginal agents (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal - therapeutic use (1) 1
anticholesteremic agents - adverse effects (1) 1
anticholesteremic agents - therapeutic use (1) 1
anticoagulants (1) 1
anticoagulants - adverse effects (1) 1
anticoagulants - therapeutic use (1) 1
aortic diseases - etiology (1) 1
apolipoprotein b (1) 1
apolipoproteins (1) 1
argentina - epidemiology (1) 1
arteriosclerosis (1) 1
ascending aorta (1) 1
assaigs clínics de medicaments (1) 1
asthma (1) 1
asthma - diagnosis (1) 1
asthma - epidemiology (1) 1
asthma - therapy (1) 1
asthma control (1) 1
asthma control questionnaire (1) 1
atherosclerotic plaque (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
by White, Harvey D and Held, Claes and Stewart, Ralph and Tarka, Elizabeth and Brown, Rebekkah and Davies, Richard Y and Budaj, Anzej and Harrington, Robert A and Steg, P. Gabriel and Ardissino, Diego and Armstrong, Paul W and Avezum, Alvaro and Aylward, Philip E and Bryce, Alfonso and Chen, Hong and Chen, Ming-Fong and Corbalan, Ramon and Dalby, Anthony J and Danchin, Nicolas and de Winter, Robbert J and Denchev, Stefan and Diaz, Rafael and Elisaf, Moses and Flather, Marcus D and Goudev, Assen R and Granger, Christopher B and Grinfeld, Liliana and Hochman, Judith S and Husted, Steen and Kim, Hyo-Soo and Koenig, Wolfgang and Linhart, Ales and Lonn, Eva and López-Sendón, José and Manolis, Athanasios J and Mohler, Emile R and Nicolau, José C and Pais, Prem and Parkhomenko, Alexander and Pedersen, Terje R and Pella, Daniel and Ramos-Corrales, Marco A and Ruda, Mikhail and Sereg, Mátyás and Siddique, Saulat and Sinnaeve, Peter and Smith, Peter and Sritara, Piyamitr and Swart, Henk P and Sy, Rody G and Teramoto, Tamio and Tse, Hung-Fat and Watson, David and Weaver, W. Douglas and Weiss, Robert and Viigimaa, Margus and Vinereanu, gos and Zhu, Junren and Cannon, Christopher P and Wallentin, Lars and Steg, Ph Gabriel and Bucan, Olga and Elfström, Charlotta and Hegg, Lisa and Jarosz, Marie and Krug-Gourley, Sue and Rudman, Jerry and Collins, Rory and Anderson, Jeffrey and DeMets, David and Ganz, Peter and Sandercock, Peter and Weber, Michael and Fisher, Marian and Buhr, Kevin and Diegel, Scott and Schultz, Melissa and Mahaffey, Kenneth W and Alexander, John H and Al-Khatib, Sana and Baron, Tomasz and Bergström, Olle and Bushnell, Cheryl and Christersson, Christina and Eggers, Kai and Fredlund, Bengt-Olov and Hagström, Emil and Hijazi, Ziad and Örndahl, Lovisa Holm and James, Stefan K and Jernberg, Tomas and Johnston, Nina and Lopez, Renato D and Mehta, Rajena H and Newby, Kristin L and Nordmark, Örjan and Oldgren, Jonas and Roe, Matthew T and Saldéen, Katarina and Stenborg, Anna and ... and The STABILITY Investigators and STABILITY Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala universitet and Institutionen för medicinska vetenskaper and Uppsala kliniska forskningscentrum (UCR)
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 18, pp. 1702 - 1711
Darapladib, an oral inhibitor of lipoprotein-associated phospholipase A2, was compared with placebo in 15,828 patients with stable coronary heart disease.... 
TRIAL | LIPOPROTEIN | MEDICINE, GENERAL & INTERNAL | THERAPY | ACTIVATING-FACTOR ACETYLHYDROLASE | OXIDIZED LDL | RISK | PHOSPHOLIPASE A | ATHEROSCLEROTIC PLAQUE | INHIBITOR | CLINICAL-OUTCOMES | Stroke - prevention & control | Double-Blind Method | Follow-Up Studies | Oximes - adverse effects | Phospholipase A2 Inhibitors - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Oximes - administration & dosage | Male | Coronary Artery Disease - drug therapy | Coronary Disease - mortality | Phospholipase A2 Inhibitors - adverse effects | Benzaldehydes - adverse effects | Benzaldehydes - administration & dosage | Coronary Artery Disease - complications | Treatment Failure | Coronary Disease - drug therapy | Female | Aged | Myocardial Infarction - prevention & control | Prevention | Care and treatment | Ischemia | Dosage and administration | Research | Coronary heart disease | Cardiovascular agents | Myocardial infarction | Cerebral infarction | Phospholipase A2 | Clinical trials | Myocardial ischemia | Cardiovascular disease | Angina | Preventive medicine | Coronary artery disease | Phospholipase | Arteriosclerosis | Death | Plasma levels | Drug therapy | Heart diseases | Plaques | Index Medicus | Abridged Index Medicus | Malalties cardiovasculars | Infart de miocardi | Malalties coronàries | Assaigs clínics de medicaments | Cardiovascular diseases | Drug testing | Coronary diseases | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
by Gerstein, Hertzel C and Colhoun, Helen M and Dagenais, Gilles and Dagenais, Gilles R and Diaz, Rafael and Diaz, Sarahy and Lakshmanan, Mark and Pais, Prem and Probstfield, Jeffrey and Riesmeyer, Jeffrey S and Riddle, Matthew C and Rydén, Lars and Xavier, Denis and Atisso, Charles Messan and Dyal, Leanne and Hall, Stephanie and Hall, Charles and Rao-Melacini, Purnima and Wong, Gloria and Avezum, Alvaro and Basile, Jan and Chung, Ming-Min and Chung, Namsik and Chung, Jin-Wook and Conget, Ignacio and Cushman, William C and Franek, Edward and Hancu, Nicolae and Hanefeld, Christoph and Hanefeld, Markolf and Holt, Shaun and Jansky, Petr and Keltai, Matyas and Keltai, Katalin and Lanas, Fernando and Leiter, Lawrence A and Lopez-Jaramillo, Patricio and Cardona Munoz, Ernesto German and Pirags, Valdis and Pogosova, Nana and Raubenheimer, Peter J and Shaw, Jonathan E and Sheu, Wayne H-H and Temelkova-Kurktschiev, Theodora and Abella, Mercedes and Alebuena, Andrea and Almagro, Sandra and Amoroso, Eduardo and Anadon, Paula and Andreu, Elizabeth and Aristimuño, Guillermo and Arzadun, Maria and Barbieri, Maria and Barcudi, Raul and Bartolacci, Ines and Bolobanich, Gabriel and Bordonava, Anselmo and Bustamante Labarta, Miguel and Bustos, Betina and Caccavo, Alberto and Camino, Alejandra and Cantero, Maria and Carignano, Maria and Cartasegna, Luis and Cipullo, Marcela and Commendatore, Víctor and Conosciuto, Victoria and Costamagna, Osvaldo and Crespo, Claudia and Cuello, Jose and Cuneo, Carlos and Cusimano, Sandra and Dean, Sofia and Dituro, Claudio and Dominguez, Andrea and Farah, Miguel and Fernandez, Alberto and Fernandez, Florencia and Ferrari, Adriana and Flammia, Patricia and Fuentealba, Jose and Gallardo, Karina Beatriz and Garcia, Mar and Garcia, Celso and Garcia, Maria and Garcia Duran, Ruben and Garrido, Marcelo and Gavicola, Rodolfo and Gerbaudo, Claudio and Gilli, Graciela and Giotto, Ana Paula and Godoy Bolzán, Pedro and Gomez Vilamajo, Oscar and Guerlloy, Fernando and Guridi, Cristian and Gutierrez Garrido, Narcisa and Hasbani, Eduardo and Hermida, Sonia and Hominal, Miguel and Hrabar, Adrian and ... and REWIND Investigators
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 121 - 130
Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk... 
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
by Bentley-Lewis, Rhonda, MD and Aguilar, David, MD and Riddle, Matthew C., MD and Claggett, Brian, PhD and Diaz, Rafael, MD and Dickstein, Kenneth, MD, PhD and Gerstein, Hertzel C., MD and Johnston, Peter, MD and Køber, Lars V., MD and Lawson, Francesca, MD and Lewis, Eldrin F., MD and Maggioni, Aldo P., MD and McMurray, John J.V., MD and Ping, Lin, MD and Probstfield, Jeffrey L., MD and Solomon, Scott D., MD and Tardif, Jean-Claude, MD and Wu, Yujun, PhD and Pfeffer, Marc A., MD, PhD and ELIXA Investigators
American Heart Journal, ISSN 0002-8703, 2015, Volume 169, Issue 5, pp. 631 - 638.e7
Background Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients... 
Cardiovascular | EXENATIDE TWICE | CARDIAC & CARDIOVASCULAR SYSTEMS | GLUCOSE CONTROL | ONCE-DAILY LIXISENATIDE | REPERFUSION INJURY | HEART-FAILURE | DOUBLE-BLIND | RECEPTOR AGONIST LIXISENATIDE | RANDOMIZED CLINICAL-TRIALS | TYPE-2 DIABETES-MELLITUS | ELEVATION MYOCARDIAL-INFARCTION | Cardiovascular Diseases | Double-Blind Method | Humans | Middle Aged | Male | Peptides - pharmacology | Acute Coronary Syndrome - drug therapy | Glucagon-Like Peptide 1 - agonists | Protein Kinase Inhibitors - therapeutic use | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Placebos | Female | Aged | p38 Mitogen-Activated Protein Kinases - metabolism | Research Design | Peptides - therapeutic use | Type 2 diabetes | Glucagon | Coronary heart disease | Analysis | Cardiovascular disease | Heart attacks | Acute coronary syndromes | Mortality | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights